Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (111-120 of 260) with videos related to

Pageof 26
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancerDavid S P Tan, Timothy A Yap, Margaret Hutka, et al.
Neuro-Oncology Advances|March 19, 2021
The promise of DNA damage response inhibitors for the treatment of glioblastomaNazanin K Majd, Timothy A Yap, Dimpy Koul, et al.
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and BiomarkersOlanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci, et al.
JCO Precision Oncology|February 9, 2022
Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair GenesTimothy A Yap, Erika Hamilton, Todd Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancerLaura Vidal, Hardev S Pandha, Timothy A Yap, et al.
Cancer Discovery|July 24, 2020
Clinical <i>BRCA1/2</i> Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy ResistanceStephen J Pettitt, Jessica R Frankum, Marco Punta, et al.
Plos One|October 6, 2017
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatmentsAnna Minchom, Parames Thavasu, Zai Ahmad, et al.
Journal of Clinical Pharmacology|November 28, 2017
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy VolunteersKarthick Vishwanathan, Paul A Dickinson, Khanh Bui, et al.
The Lancet. Oncology|February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trialsTimothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
Pageof 26

Showing results (111-120 of 260) with videos related to

Sort By:
Pageof 26
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancerDavid S P Tan, Timothy A Yap, Margaret Hutka, et al.
Neuro-Oncology Advances|March 19, 2021
The promise of DNA damage response inhibitors for the treatment of glioblastomaNazanin K Majd, Timothy A Yap, Dimpy Koul, et al.
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and BiomarkersOlanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci, et al.
JCO Precision Oncology|February 9, 2022
Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair GenesTimothy A Yap, Erika Hamilton, Todd Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancerLaura Vidal, Hardev S Pandha, Timothy A Yap, et al.
Cancer Discovery|July 24, 2020
Clinical <i>BRCA1/2</i> Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy ResistanceStephen J Pettitt, Jessica R Frankum, Marco Punta, et al.
Plos One|October 6, 2017
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatmentsAnna Minchom, Parames Thavasu, Zai Ahmad, et al.
Journal of Clinical Pharmacology|November 28, 2017
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy VolunteersKarthick Vishwanathan, Paul A Dickinson, Khanh Bui, et al.
The Lancet. Oncology|February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trialsTimothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
Pageof 26